Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Pfizer’s Drug Improves Survival in Kidney Cancer Trial

By Ryan Bushey | October 11, 2016

Roman Tiraspolsky / Shutterstock.com

Pfizer’s kidney cancer drug received mixed results over the weekend from two studies.

The company’s drug, Sutent, improved the median disease-free survival rates for patients who had localized kidney cancer that was removed via surgery, reported FiercePharma. These individuals tend to be high-risk for relapses.

Investigators running this trial, named S-TRAC, monitored patients who took a one year regimen of either Sutent or a placebo for a five-year period. The median disease-free survival rate in the Sutent group was 6.8 years while it stood at 5.6 years for the other set.

Also, this is the first positive adjuvant renal cell cancer (RCC) trial.

“For the past 10 years, Pfizer has been a leader in developing new treatments for patients with kidney cancer, and Sutent has been the most widely prescribed first-line treatment for thousands of patients with advanced RCC around the world,” said Mace Rothenberg, MD, Chief Development Officer, Oncology, Pfizer Global Product Development in a statement.

The results of S-TRAC suggest that SUTENT has the potential to extend this benefit by reducing the risk of recurrence in patients who have undergone complete surgical removal of their kidney cancer and are at high risk of cancer recurrence,” he continued.

However, Sutent didn’t fare as well in another study testing it against a rival drug called Cabometyx made by Elexlixis to treat metastatic kidney cancer, wrote Reuters.

Results from a Phase 2 study indicated Cabometyx caused a 31 percent reduction in disease progression or death when compared to Pfizer’s product. Volunteers taking Sutent experienced an increase of 5.6 months before the disease worsened while patients on a Cabometyx regimen experienced on average an 8.2 month period before their condition worsened.

Still, both companies are pleased with the results. Exelixis plans on filing a regulatory approval to sell their drug as a first-line advanced kidney cancer treatment whereas Pfizer is seeking to add another indication for Sutent to treat RCC.


Filed Under: Drug Discovery

 

Related Articles Read More >

Sai Life Sciences exec: GLP-1 boom has ‘exploded the peptide field’ as firm opens new center
Novartis in the Pharma 50
Swissmedic approves first malaria treatment for infants
Korean team reports all-in-one cancer nanomedicine in pre-clinical studies
Nektar’s Phase 2b atopic dermatitis win triggers 1,746% analyst target surge, but legal tussle with ex-partner Lilly could complicate path forward
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE